Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)

NCT00430612 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the PACE-MI (OBTAIN) registry is: * Analyze beta-blocker dose response effect on outcome over two years * Explore gender and minority differences in beta-blocker utilization and outcomes. In patients with Myocardial Infarction (MI) discharged from the hospital, beta-blocker dose will be predictive of survival. Exploratory analyses: Gender and racial effects-gender and race are, similarly, hypothesized to be predictive of post-MI survival. The existence of interactions between gender and beta-blocker effect as well as race and beta-blocker effect will also be evaluated.

Conditions Studied

Study Locations (20)

New York

  • Winthrop University Hospital — Bethpage
  • Maimonides Medical Center — Brooklyn
  • Strong Memorial Hospital (University of Rochester School of Medicine) — Rochester

California

  • MemorialCare Heart and Vascular Institute - Long Beach Memorial Medical Center — Long Beach
  • West Los Angeles VA Medical Center — Los Angeles

Florida

  • Baptist Cardiac and Vascular Institute — Miami
  • Orlando Regional Medical Center — Orlando

Texas

  • Amarillo Heart Clinic Research Institute, Inc. — Amarillo
  • Austin Heart PLLC — Austin

Arkansas

  • Little Rock Cardiology Clinic — Little Rock

Connecticut

  • Bridgeport Hospital — Bridgeport

Illinois

  • Northwestern Memorial Hospital — Chicago

Indiana

  • Clarian Health/Methodist Research Institute — Indianapolis

Trial Details

FieldValue
Enrollment Target 7,057 participants
Start Date 2009-05
Est. Completion 2015-10

Sponsor

Northwestern University

1,033 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00430612

The ClinicalTrials.gov registry entry for NCT00430612 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 7,057 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,033 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00430612 reports 20 study locations spanning 15 distinct geographic areas — top geographies include New York, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00430612 about?

NCT00430612 is a clinical study titled "The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)". The purpose of the PACE-MI (OBTAIN) registry is: * Analyze beta-blocker dose response effect on outcome over two years * Explore gender and minority differences in beta-blocker utilization and outcomes. In patients with Myocardial Infarction (MI) discharged from the hospital, beta-blocker dose wil...

What is the current status of trial NCT00430612?

This trial is currently completed. The enrollment target is 7,057 participants. The study started on 2009-05. Estimated completion is 2015-10.

What conditions does trial NCT00430612 study?

This clinical trial studies the following conditions: Myocardial Infarction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT00430612?

This trial is sponsored by Northwestern University, which has 1,033 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00430612 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial